Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 9/20 | 0.53 |
| ▸ | CA2 | P00918 | 9/20 | 0.53 |
| ▸ | CA12 | O43570 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL17818451 | 0.98 | TDP1 (0.62) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL30183864 | 0.98 | TDP1 (0.62) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL691053 | 0.96 | TDP1 (0.70) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL14571199 | 0.94 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL21996829 | 0.94 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL12772839 | 0.94 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1588079 | 0.94 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL569251 | 0.92 | TDP1 (0.74) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7771476 | 0.88 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL46654 | 0.88 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747243-A1 | LIGANDS AND COMPOSITIONS AND METHODS OF USE THEREOF | Baylor College of Medicine (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-122036541-A | Amino acid-based ionizable lipid compound, and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3983081-B1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4703355-A1 | FLUORINE-CONTAINING ISOXAZOLONE COMPOUND AND PRODUCTION METHOD FOR SAME | Unimatec Co., Ltd. (JP) | 2026-03-04 | — | — | EP | disclosed |
| EP-4687854-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | Flagship Labs 114, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORP (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007062411-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5-YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004026846-A1 | DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | DCLK2, TH, DCLK3 | TDP1 528/4885MEN1 1611/4885GAA 4103/4885 |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | TDP1 3765/4885MEN1 4731/4885GAA 4162/4885 |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | TDP1 480/4885MEN1 4048/4885GAA 2406/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | TDP1 3952/4885MEN1 3960/4885GAA 3879/4885 |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | MDM2, TP53, VHL | TDP1 1244/4885MEN1 2924/4885GAA 949/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | TDP1 4423/4885MEN1 1870/4885GAA 4234/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | TDP1 3130/4885MEN1 4805/4885GAA 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.